Karuna seeks a novel schizophrenia mechanism
Pivotal data will show whether KarXT can walk the risk-benefit tightrope.
The mystery of Jemperli’s rectal cancer breakthrough
If Jemperli might effectively cure a biomarker-defined subset of rectal cancer patients why isn't pharma more interested?
EHA 2022 – Crispr still looks bloody good
Updated data with exa-cel in sickle cell disease and beta-thalassaemia could put the fear into competitors.
EHA 2022 – Caribou’s turn to run into allo Car-T relapses
The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
Asco 2022 movers – cell therapy wins, but it’s not the whole story
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
Asco 2022 – Can Daiichi do it again?
The Japanese drug maker has four more conjugates coming behind Enhertu, and plans to keep future successes to itself.
ADA 2022 – Move over Mounjaro?
Lilly believes it has two promising new molecules for diabetes and obesity. But which to choose – and might toxicity yet scupper one or both?
